{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:09:44Z","timestamp":1790640584014,"version":"4.1.0"},"reference-count":36,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>One challenge of chimeric antigen receptor T-cell therapy (CAR-T) for relapsed or refractory large B-cell lymphoma (LBCL) is achieving disease control during manufacturing. We report real-word outcomes of 100 patients treated with axicabtagene ciloleucel (axi-cel, n = 50) or tisagenlecleucel (tisa-cel, n = 50) at our center. Most patients received bridging therapy (BT) with 48 undergoing radiation BT (RBT) and 32 receiving systemic BT (SBT). The best overall response rate (ORR) was 84% (78% complete response (CR)) for axi-cel and 60% (42% CR) for tisa-cel. At a median follow-up of 16 months, 12-month progression-free survival (PFS) and overall survival (OS) were 72% and 82% for axi-cel, compared to 35% and 57% for tisa-cel. By the bridging approach, 12-month PFS was 60% with RBT, 59% without BT and 35% with SBT (p = 0.06). Notably, axi-cel patients without lymphoma progression during manufacturing (n = 24) achieved 12-month PFS and OS rates of 91% and 96%, respectively. Axi-cel was associated with more cytokine release syndrome (92% vs. 66%, p = 0.003) and neurotoxicity (all-grade 56% vs. 10%, p &lt; 0.001, grade \u2265 328% vs. 4%, p = 0.002). Multivariate analysis identified RBT as independently associated with improved PFS (HR 0.46, 95% CI 0.22\u20130.96). Pending prospective validation, RBT shows promise for improving CAR-T outcomes in LBCL.<\/jats:p>","DOI":"10.3390\/curroncol32030173","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T08:57:02Z","timestamp":1742201822000},"page":"173","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Enhancing CAR-T Efficacy in Large B-Cell Lymphoma with Radiation Bridging Therapy: A Real-World Single-Center Experience"],"prefix":"10.3390","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8722-8419","authenticated-orcid":false,"given":"Eva","family":"Laverdure","sequence":"first","affiliation":[{"name":"Department of Medicine, Institut Universitaire d\u2019H\u00e9mato-Oncologie et de Th\u00e9rapie Cellulaire, H\u00f4pital Maisonneuve-Rosemont, CIUSSS de l\u2019Est-de-l\u2019\u00cele-de-Montr\u00e9al, l, Montr\u00e9al, QC HIT 2M4, Canada"},{"name":"Department of Hemato-Oncology, H\u00f4pital Fleurimont, Centre Hospitalier Universitaire de Sherbrooke, CIUSSS de l\u2019Estrie, Facult\u00e9 de M\u00e9decine et des Sciences de la Sant\u00e9, Universit\u00e9 de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada"},{"name":"Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H2V 0B3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigina","family":"Mollica","sequence":"additional","affiliation":[{"name":"Department of Medicine, Institut Universitaire d\u2019H\u00e9mato-Oncologie et de Th\u00e9rapie Cellulaire, H\u00f4pital Maisonneuve-Rosemont, CIUSSS de l\u2019Est-de-l\u2019\u00cele-de-Montr\u00e9al, l, Montr\u00e9al, QC HIT 2M4, Canada"},{"name":"Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H2V 0B3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1899-0164","authenticated-orcid":false,"given":"Imran","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Department of Medicine, Institut Universitaire d\u2019H\u00e9mato-Oncologie et de Th\u00e9rapie Cellulaire, H\u00f4pital Maisonneuve-Rosemont, CIUSSS de l\u2019Est-de-l\u2019\u00cele-de-Montr\u00e9al, l, Montr\u00e9al, QC HIT 2M4, Canada"},{"name":"Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H2V 0B3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Institut Universitaire d\u2019H\u00e9mato-Oncologie et de Th\u00e9rapie Cellulaire, H\u00f4pital Maisonneuve-Rosemont, CIUSSS de l\u2019Est-de-l\u2019\u00cele-de-Montr\u00e9al, l, Montr\u00e9al, QC HIT 2M4, Canada"},{"name":"Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H2V 0B3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7882-9335","authenticated-orcid":false,"given":"Silvy","family":"Lachance","sequence":"additional","affiliation":[{"name":"Department of Medicine, Institut Universitaire d\u2019H\u00e9mato-Oncologie et de Th\u00e9rapie Cellulaire, H\u00f4pital Maisonneuve-Rosemont, CIUSSS de l\u2019Est-de-l\u2019\u00cele-de-Montr\u00e9al, l, Montr\u00e9al, QC HIT 2M4, Canada"},{"name":"Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H2V 0B3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7029-1769","authenticated-orcid":false,"given":"Olivier","family":"Veilleux","sequence":"additional","affiliation":[{"name":"Department of Medicine, Institut Universitaire d\u2019H\u00e9mato-Oncologie et de Th\u00e9rapie Cellulaire, H\u00f4pital Maisonneuve-Rosemont, CIUSSS de l\u2019Est-de-l\u2019\u00cele-de-Montr\u00e9al, l, Montr\u00e9al, QC HIT 2M4, Canada"},{"name":"Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H2V 0B3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5510-5036","authenticated-orcid":false,"given":"Maryse","family":"Bernard","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H2V 0B3, Canada"},{"name":"Department of Radiation Therapy, Institut Universitaire d\u2019H\u00e9mato-Oncologie et de Th\u00e9rapie Cellulaire, H\u00f4pital Maisonneuve-Rosemont, CIUSSS de l\u2019Est-de-l\u2019\u00cele-de-Montr\u00e9al, Montr\u00e9al, QC H1T 2M4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0618-3260","authenticated-orcid":false,"given":"Eve-Lyne","family":"Marchand","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H2V 0B3, Canada"},{"name":"Department of Radiation Therapy, Institut Universitaire d\u2019H\u00e9mato-Oncologie et de Th\u00e9rapie Cellulaire, H\u00f4pital Maisonneuve-Rosemont, CIUSSS de l\u2019Est-de-l\u2019\u00cele-de-Montr\u00e9al, Montr\u00e9al, QC H1T 2M4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1460-7287","authenticated-orcid":false,"given":"Jean-S\u00e9bastien","family":"Delisle","sequence":"additional","affiliation":[{"name":"Department of Medicine, Institut Universitaire d\u2019H\u00e9mato-Oncologie et de Th\u00e9rapie Cellulaire, H\u00f4pital Maisonneuve-Rosemont, CIUSSS de l\u2019Est-de-l\u2019\u00cele-de-Montr\u00e9al, l, Montr\u00e9al, QC HIT 2M4, Canada"},{"name":"Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H2V 0B3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Bernard","sequence":"additional","affiliation":[{"name":"Department of Medicine, Institut Universitaire d\u2019H\u00e9mato-Oncologie et de Th\u00e9rapie Cellulaire, H\u00f4pital Maisonneuve-Rosemont, CIUSSS de l\u2019Est-de-l\u2019\u00cele-de-Montr\u00e9al, l, Montr\u00e9al, QC HIT 2M4, Canada"},{"name":"Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H2V 0B3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lissa","family":"Boileau","sequence":"additional","affiliation":[{"name":"Department of Medicine, Institut Universitaire d\u2019H\u00e9mato-Oncologie et de Th\u00e9rapie Cellulaire, H\u00f4pital Maisonneuve-Rosemont, CIUSSS de l\u2019Est-de-l\u2019\u00cele-de-Montr\u00e9al, l, Montr\u00e9al, QC HIT 2M4, Canada"},{"name":"Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H2V 0B3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7099-8107","authenticated-orcid":false,"given":"Tony","family":"Petrella","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H2V 0B3, Canada"},{"name":"Department of Pathology, Institut Universitaire d\u2019H\u00e9mato-Oncologie et de Th\u00e9rapie Cellulaire, H\u00f4pital Maisonneuve-Rosemont, CIUSSS de l\u2019Est-de-l\u2019\u00cele-de-Montr\u00e9al, Montr\u00e9al, QC H1T 2M4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah-Jeanne","family":"Pilon","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H2V 0B3, Canada"},{"name":"Department of Pathology, Institut Universitaire d\u2019H\u00e9mato-Oncologie et de Th\u00e9rapie Cellulaire, H\u00f4pital Maisonneuve-Rosemont, CIUSSS de l\u2019Est-de-l\u2019\u00cele-de-Montr\u00e9al, Montr\u00e9al, QC H1T 2M4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0635-6086","authenticated-orcid":false,"given":"Philippe","family":"Bouchard","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Institut Universitaire d\u2019H\u00e9mato-Oncologie et de Th\u00e9rapie Cellulaire, H\u00f4pital Maisonneuve-Rosemont, CIUSSS de l\u2019Est-de-l\u2019\u00cele-de-Montr\u00e9al, Montr\u00e9al, QC H1T 2M4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5921-1692","authenticated-orcid":false,"given":"Denis-Claude","family":"Roy","sequence":"additional","affiliation":[{"name":"Department of Medicine, Institut Universitaire d\u2019H\u00e9mato-Oncologie et de Th\u00e9rapie Cellulaire, H\u00f4pital Maisonneuve-Rosemont, CIUSSS de l\u2019Est-de-l\u2019\u00cele-de-Montr\u00e9al, l, Montr\u00e9al, QC HIT 2M4, Canada"},{"name":"Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H2V 0B3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5375-3749","authenticated-orcid":false,"given":"Lambert","family":"Busque","sequence":"additional","affiliation":[{"name":"Department of Medicine, Institut Universitaire d\u2019H\u00e9mato-Oncologie et de Th\u00e9rapie Cellulaire, H\u00f4pital Maisonneuve-Rosemont, CIUSSS de l\u2019Est-de-l\u2019\u00cele-de-Montr\u00e9al, l, Montr\u00e9al, QC HIT 2M4, Canada"},{"name":"Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H2V 0B3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Fleury","sequence":"additional","affiliation":[{"name":"Department of Medicine, Institut Universitaire d\u2019H\u00e9mato-Oncologie et de Th\u00e9rapie Cellulaire, H\u00f4pital Maisonneuve-Rosemont, CIUSSS de l\u2019Est-de-l\u2019\u00cele-de-Montr\u00e9al, l, Montr\u00e9al, QC HIT 2M4, Canada"},{"name":"Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H2V 0B3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_3","first-page":"581.e1-581.e8","article-title":"Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant. Cell Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bjh.18209","article-title":"A national service for delivering CD19 CAR-Tin large B-cell lymphoma\u2014The UK real-world experience","volume":"198","author":"Kuhnl","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_5","first-page":"349","article-title":"GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany","volume":"140","author":"Bethge","year":"2022","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat. Med."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Bastos-Oreiro, M., Gutierrez, A., Reguera, J.L., Iacoboni, G., Lopez-Corral, L., Terol, M.J., Ortiz-Maldonado, V., Sanz, J., Guerra-Dominguez, L., and Bailen, R. (2022). Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO\/GETH Spanish Groups. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.855730"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1182\/blood-2022-158822","article-title":"Real-World Outcomes for Patients with Relapsed or Refractory (R\/R) Aggressive B-Cell Non-Hodgkin\u2019s Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Subgroup Analyses from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry","volume":"140","author":"Landsburg","year":"2022","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: Primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: The phase 2 ZUMA-12 trial","volume":"28","author":"Neelapu","year":"2022","journal-title":"Nat. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1182\/bloodadvances.2020001837","article-title":"Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma","volume":"4","author":"Pinnix","year":"2020","journal-title":"Blood Adv."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1182\/bloodadvances.2022009019","article-title":"Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma","volume":"7","author":"Roddie","year":"2023","journal-title":"Blood Adv."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/jha2.335","article-title":"Role of bridging therapy during chimeric antigen receptor T cell therapy","volume":"3","author":"Bhaskar","year":"2022","journal-title":"EJHaem"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.ijrobp.2022.12.017","article-title":"Don\u2019t Put the CART Before the Horse: The Role of Radiation Therapy in Peri-CAR T-cell Therapy for Aggressive B-cell Non-Hodgkin Lymphoma","volume":"116","author":"Saifi","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Ladbury, C., Dandapani, S., Hao, C., Fabros, M., Amini, A., Sampath, S., Glaser, S., Sokolov, K., Yeh, J., and Baird, J.H. (2023). Long-Term Follow-Up of Bridging Therapies Prior to CAR T-Cell Therapy for Relapsed\/Refractory Large B Cell Lymphoma. Cancers, 15.","DOI":"10.3390\/cancers15061747"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"259.1-259.e10","DOI":"10.1016\/j.jtct.2022.12.021","article-title":"Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed\/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell Therapy","volume":"29","author":"Hubbeling","year":"2023","journal-title":"Transplant. Cell Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/bloodadvances.2019000952","article-title":"Comparing CAR T-cell toxicity grading systems: Application of the ASTCT grading system and implications for management","volume":"4","author":"Pennisi","year":"2020","journal-title":"Blood Adv."},{"key":"ref_20","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): A multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e2250039","DOI":"10.1002\/eji.202250039","article-title":"Four challenges to CAR T cells breaking the glass ceiling","volume":"53","author":"Bailey","year":"2023","journal-title":"Eur. J. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5995","DOI":"10.1182\/bloodadvances.2021006923","article-title":"A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma","volume":"6","author":"Thieblemont","year":"2022","journal-title":"Blood Adv."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-024-01022-w","article-title":"Reducing and controlling metabolic active tumor volume prior to CAR T-cell infusion can improve survival outcomes in patients with large B-cell lymphoma","volume":"14","author":"Keijzer","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3324\/haematol.2022.280805","article-title":"Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma","volume":"108","author":"Kwon","year":"2023","journal-title":"Haematologica"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12943-023-01775-1","article-title":"CAR T cell-based immunotherapy and radiation therapy: Potential, promises and risks","volume":"22","author":"Hovhannisyan","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/j.ijrobp.2023.06.333","article-title":"Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas: An ILROG Multi-Institutional Study","volume":"117","author":"Wright","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/ajh.27155","article-title":"Incorporating radiation with anti-CD19 chimeric antigen receptor T-cell therapy for relapsed\/refractory non-Hodgkin lymphoma: A multicenter consensus approach","volume":"99","author":"Saifi","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ijrobp.2020.05.014","article-title":"Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma","volume":"108","author":"Wright","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.ijrobp.2019.05.065","article-title":"Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma","volume":"105","author":"Sim","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ijrobp.2016.01.039","article-title":"Palliative Radiation Therapy for Advanced Head and Neck Carcinomas: A Phase 2 Study","volume":"95","author":"Fortin","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1182\/blood.2020006028","article-title":"ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic","volume":"135","author":"Yahalom","year":"2020","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e483","DOI":"10.1016\/j.ijrobp.2023.06.1708","article-title":"Outcomes with Bridging Radiation Therapy Prior to CAR-T Cell Therapy in Pts with Aggressive B Cell Lymphomas","volume":"117","author":"Manzar","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamaoncol.2024.1113","article-title":"Comprehensive Bridging Radiotherapy for Limited Pre-CART Non-Hodgkin Lymphoma","volume":"10","author":"Saifi","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.semradonc.2024.10.005","article-title":"The Role of Radiotherapy in Lymphoma Patients Undergoing CAR T Therapy: Past, Present, and Future","volume":"35","author":"Wallington","year":"2025","journal-title":"Semin. Radiat. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/3\/173\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:55:02Z","timestamp":1760028902000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/3\/173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["curroncol32030173"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32030173","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]}}}